ClinicalTrials.gg
RecruitingNCT06975579COSIEUpdated May 16, 2025

The COherence of Scatter Identification and Exclusion Algorithm Study

An observational study in Steatohepatitis, Nonalcoholic, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Institute of Cancer Research, United Kingdom · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.

Planned enrollment
21st of 21
15 · median 153
Started
2024
with 6 others
Observational
21 of 122
5 open now
Primary completion
2025-06
later than 3 of 26 live
Registered
119th of 122
by date

Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 21st largest by planned enrollment of the 21 observational ones that give a count, is one of 7 that started in 2024, is one of 21 observational ones, reaches primary completion later than 3 of the 26 other live ones, and was the 119th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an unwanted side effect of common cancer therapies, such as chemotherapy. Ultrasound can detect NAFLD via measurement of the backscatter coefficient (BSC). It is an attractive technique because of its low cost and availability, potentially enabling earlier detection of NAFLD in a larger population through screening. This approach has shown promise in detecting NAFLD but is limited by variability in measurement due to several factors. Measurement of the BSC requires assumptions about the nature of the tissue being measured; if these assumptions are incorrect, they can lead to inaccurate BSC measurements. To improve accuracy, an algorithm (COSIE) was developed to quantify the suitability of tissue for BSC analysis. The investigators believe COSIE will enable more reliable BSC measurements by selecting the optimal regions of tissue to measure. By measuring the BSC in the livers of healthy volunteers and patients with evidence of fatty liver, the algorithm can be evaluated against liver fat percentage values obtained from MRI imaging. This study will assess whether applying the COSIE algorithm enhances the reliability of BSC measurements, bringing them closer in quality to MRI imaging.

03

Conditions studied

  • Steatohepatitis, Nonalcoholic

Keywords

  • Liver ultrasound
  • backscatter coefficient
  • Non-alcoholic fatty liver disease
  • steatosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

It is assumed that these volunteers will display a range of liver fat fractions and that there may be bias towards the low-fat fractions (\< 5%). Patients with known fatty liver are included to present a broader range of cases to consider, thereby improving the analysis. If a patient is MR scanned and it is found that they have low fat fraction, we will aim to replace them with another patient that does have a high fat fraction.

This number has been selected without a priori predictions of the expected variance in results. This study will help to determine the necessary study power required for future investigations. This population size has been selected based on practical considerations, i.e. cost of MR and length of the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Volunteers:

  • Healthy male or female adults (18 or above).
  • Volunteers must consider themselves fit and healthy.
  • RMH and/or ICR employees.

Patients:

  • Patients undergoing liver MRI as part of clinical standard of care with evidence of steatosis on preceding MRI.
  • Aged 18 and above.

Exclusion criteria

Exclusion Criteria:

Healthy Volunteers:

  • Volunteers that are under investigation or planning to consult their GP to seek investigation for an undiagnosed condition, particularly regarding pelvic or abdominal disease or injury.
  • Healthy volunteers who do not have an NHS number or who are not registered with a GP will be excluded.

Patients:

  • Severe liver fibrosis (fibrosis stage F4) or severe cirrhosis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Volunteers

    Staff at Royal Marsden Hospital or Institute of Cancer Research

    Device: Ultrasound image processing

  • Patients

    Patients undergoing therapy/follow up for cancer with some evidence of non-alcoholic fatty liver disease.

    Device: Ultrasound image processing

Interventions

  • DeviceUltrasound image processing

    The COSIE study examines the coherence of ultrasound to improve the estimation of the backscatter coefficient.

06

What researchers measure

Primary outcomes

  1. Difference in backscatter coefficient

    Mean difference in repeat measures of backscatter coefficient (BSC) in the liver with and without application of COSIE, across all participants and all views.

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised ultrasound and MR images will be shared upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2025, 10 months after the start.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 10 months is below that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 16, 2025
StartActual
Aug 27, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06975579
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Aug 27, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
May 16, 2025

Study contacts

Emma J Harris, PhD
Contact
emma.harris@icr.ac.uk
+442087224576

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion